background
respiratori
syncyti
viru
rsv
major
caus
respiratori
infect
children
palivizumab
pz
rsvspecif
immunoprophylaxi
approv
us
food
drug
administr
mutat
lead
amino
acid
substitut
pz
bind
site
rsv
f
protein
associ
breakthrough
rsv
infect
patient
receiv
pz
object
detect
pz
resist
confer
mutat
rsv
strain
children
receiv
pz
studi
design
children
age
month
octob
hospit
outpati
visit
respiratori
ill
andor
fever
octobermay
us
counti
includ
pz
receipt
obtain
parent
interview
medic
record
among
children
subsequ
infect
rsv
archiv
nasalthroat
swab
specimen
test
rsv
realtim
rtpcr
code
region
pz
bind
site
rsv
f
protein
sequenc
use
sanger
pyrosequenc
method
result
enrol
children
test
rsv
histori
pz
receipt
rsvposit
avail
archiv
specimen
molecular
type
identifi
partial
f
gene
sequenc
specimen
children
singl
rsv
subgroup
subgroup
b
mix
infect
nucleotid
substitut
identifi
rsv
strain
pz
resist
mutat
identifi
children
one
document
pz
receipt
conclus
although
rsv
pz
resist
mutat
infrequ
rsvassoci
ill
children
histori
pz
receipt
due
strain
resist
publish
elsevi
bv
respiratori
syncyti
viru
rsv
lead
caus
acut
respiratori
infect
result
hospit
admiss
death
among
children
year
worldwid
estim
global
mortal
due
rsv
infect
death
children
year
age
death
develop
countri
infant
born
prematur
chronic
lung
cardiac
diseas
increas
risk
sever
diseas
rsv
infect
palivizumab
pz
brand
name
synagi
medimmun
inc
gaithersburg
md
human
igg
monoclon
antibodi
neutral
rsv
inhibit
viral
fusion
interact
site
span
residu
rsv
fusion
glycoprotein
f
pz
prophylaxi
approv
us
food
drug
administr
rsv
infect
five
monthli
pz
inject
span
annual
rsv
epidem
period
shown
reduc
hospit
among
highrisk
children
us
howev
high
mutat
rate
found
rna
virus
allow
readi
escap
immun
pressur
antibodi
select
pzresist
rsv
strain
cell
cultur
anim
system
http
elsevi
bv
well
describ
includ
mutant
select
murin
parent
pz
increas
use
pz
highrisk
children
immunocompromis
person
might
provid
opportun
pz
resist
mutant
aris
potenti
sustain
transmiss
other
previou
report
shown
mutat
lead
amino
acid
substitut
pz
bind
site
rsv
f
protein
includ
associ
breakthrough
infect
patient
receiv
pz
prophylaxi
extent
mutat
occur
well
known
studi
analyz
rsv
strain
obtain
patient
prospect
enrol
new
vaccin
surveil
network
nvsn
activ
surveil
acut
respiratori
ill
andor
fever
ari
us
experienc
rsv
infect
report
pz
receipt
order
identifi
pz
resist
confer
mutat
f
gene
code
region
pz
bind
site
present
studi
aim
detect
pz
resist
confer
mutat
rsv
strain
identifi
children
receiv
pz
nvsn
enrol
children
admit
hospit
seen
outpati
ari
resid
us
counti
monro
counti
new
york
davidson
counti
tennesse
hamilton
counti
ohio
obtain
inform
consent
accord
standard
protocol
previous
describ
midturbin
nasal
throat
swab
specimen
obtain
enrol
children
test
rsv
rtpcr
viral
cultur
site
research
laboratori
demograph
medic
histori
clinic
data
obtain
medic
record
parent
report
document
prematur
birth
obtain
studi
includ
subset
children
enrol
octob
may
month
age
octob
histori
pz
receipt
obtain
first
interview
parentsguardian
parent
enrol
children
ask
whether
child
receiv
pz
inject
current
rsv
season
children
rsvposit
site
test
whose
parent
report
pz
receipt
studi
staff
retrospect
contact
healthcar
provid
confirm
receipt
pz
date
dose
archiv
frozen
c
combin
nasal
throat
swab
specimen
rsvposit
children
parent
report
pz
receipt
ship
center
diseas
control
prevent
cdc
molecular
analysi
total
nucleic
acid
extract
sampl
use
nuclisen
easymag
extract
test
rsv
realtim
rtpcr
rrtpcr
assay
describ
fri
et
al
posit
sampl
subject
rtpcr
sequenc
f
gene
region
encod
pz
bind
site
use
follow
primer
set
forward
primer
biotinyl
facilit
pyrosequec
rsv
fwd
taactacacctgtaagcac
rev
acatgatagagtaactttgc
rsv
b
fwd
rev
rtpcr
amplif
perform
use
superscript
iii
onestep
rtpcr
system
invitrogen
life
technolog
amplicon
rsv
bp
rsv
b
bp
purifi
use
exosapit
amersham
pharmacia
biotech
piscataway
nj
usa
two
sequenc
procedur
appli
sanger
sequenc
genet
analyz
life
technolog
grand
island
ny
usa
pyrosequenc
pyromark
instrument
biotag
ab
uppsala
sweden
use
procedur
newli
develop
studi
avail
request
sanger
sequenc
amplicon
subject
forward
revers
cycl
sequenc
use
bigdy
termin
sequenc
kit
appli
biosystem
life
technolog
semiquantit
pyrosequenc
perform
target
design
mutat
site
known
alter
pz
suscept
codon
analys
perform
pyromark
analysi
softwar
use
allel
quantif
frequenc
mode
allel
test
calibr
curv
gener
standard
prepar
follow
proport
wildtyp
wt
mutant
allel
calibr
standard
includ
run
perform
triplic
dilut
limit
detect
allel
estim
measur
signal
obtain
known
neg
respiratori
swab
sampl
wt
calcul
posit
respons
cutoff
wt
wt
exclud
possibl
viral
etiolog
specimen
identifi
rsv
pz
resist
strain
also
test
panel
cdc
hous
rtpcr
assay
influenza
human
metapneumoviru
parainfluenza
viru
type
adenoviru
rhinoviru
coronavirus
base
recommend
pz
dose
schedul
total
monthli
dose
rsv
season
defin
rsv
infect
lead
medic
visit
ari
occur
within
day
last
confirm
pz
dose
breakthrough
infect
among
enrol
children
met
age
criteria
studi
receiv
pz
accord
parent
report
tabl
fig
test
rsv
surveil
site
posit
archiv
specimen
avail
rsvposit
children
sent
cdc
confirmatori
test
sequenc
confirm
posit
rsv
rrtpcr
remain
specimen
neg
cdc
rsv
rrtpcr
rtpcr
assay
molecular
type
identifi
partial
f
gene
sequenc
specimen
singl
rsv
subgroup
singl
rsv
subgroup
b
codetect
singl
rsv
b
codetect
differ
rsv
b
sequenc
rsv
b
strain
cocircul
year
altern
predomin
studi
period
tabl
partial
rsv
f
gene
sequenc
obtain
nucleotid
substitut
includ
rsv
subgroup
rsv
subgroup
b
strain
mutat
synonym
encod
predict
amino
acid
chang
recogn
confer
pz
resist
tabl
analysi
sequenc
chromatogram
pyrogram
pz
resist
strain
reveal
specimen
wt
allel
present
rsv
c
nt
posit
c
nt
posit
rsv
b
g
nt
posit
c
nt
posit
fig
specimen
contain
rsv
pz
resist
strain
rtpcr
neg
respiratori
virus
children
parent
report
pz
receipt
rsv
f
gene
sequenc
avail
document
medic
record
confirm
prior
receipt
pz
current
rsv
season
children
confirm
pz
receipt
children
lack
medic
record
pz
receipt
underli
medic
condit
prematur
birth
born
week
earli
parent
report
among
confirm
pz
receipt
receiv
pz
within
day
prior
ari
hospit
outpati
visit
indic
met
studi
definit
breakthrough
infect
tabl
pz
also
receiv
day
prior
report
onset
ill
breakthrough
infect
one
possess
known
pz
resist
mutat
pz
recipi
infect
resist
rsv
strain
receiv
pz
within
day
window
one
dose
date
note
medic
record
studi
identifi
rsv
strain
nucleotid
substitut
code
region
f
gene
pz
bind
site
predict
confer
pz
resist
children
medic
care
visit
rsv
parent
report
prior
receipt
pz
season
howev
abl
confirm
breakthrough
infect
children
pz
receipt
andor
date
pz
dose
unavail
medic
record
studi
children
children
infect
rsv
strain
associ
pz
resist
suggest
resist
account
major
pz
failur
although
pz
bind
site
rsv
f
protein
highli
conserv
multipl
year
surveil
found
frequenc
resist
confer
mutat
similar
report
two
tabl
characterist
palivizumab
pz
recipi
record
dose
schedul
studi
similar
patient
popul
pz
receipt
prior
ill
one
studi
report
mutat
frequenc
among
highrisk
infant
lower
respiratori
tract
ill
second
studi
report
mutat
among
patient
age
year
respiratori
tract
ill
appar
breakthrough
rsv
infect
occur
immunoprophylaxi
could
due
improp
space
pz
dose
exposur
high
viru
concentr
frailti
pz
recipi
occult
coinfect
respiratori
pathogen
except
none
pz
resist
strain
identifi
studi
shown
occur
natur
therefor
like
aros
pz
select
mutat
origin
describ
patient
rsv
breakthrough
infect
shown
exhibit
increas
pz
resist
vitro
base
microneutr
assay
howev
recent
report
shown
rsv
natur
occur
effort
confirm
pz
resist
microneutr
assay
fail
interest
note
consensu
sequenc
rsv
b
virus
breakthrough
strain
identifi
rsv
subgroup
b
possess
suggest
b
strain
may
inher
resist
pz
whose
murin
parent
develop
rsv
strain
altern
exclud
possibl
coincid
mutat
outsid
pz
bind
region
may
contribut
pz
resist
infect
simpli
occur
reason
note
novel
pyrosequenc
method
appli
directli
clinic
specimen
prove
use
identifi
low
level
variant
sequenc
might
present
quasispeci
popul
pyrosequenc
permit
rapid
sensit
semiquantit
estim
rel
preval
wt
allel
sampl
sampl
identifi
pyrosequenc
mix
sequenc
would
miss
use
sanger
sequenc
alon
pyrosequenc
reveal
mix
infect
wildtyp
n
allel
predomin
except
present
small
fraction
total
sampl
sequenc
make
difficult
case
attribut
patient
ill
breakthrough
infect
studi
limit
estim
true
rate
breakthrough
infect
parent
recal
pz
receipt
may
inaccur
challeng
obtain
pz
record
retrospect
compound
failur
locat
archiv
specimen
confirm
specimen
origin
report
rsvposit
studi
rsvneg
infant
detail
similar
challeng
determin
retrospect
children
strictli
met
criteria
pz
receipt
recommend
receiv
obtain
document
receipt
note
howev
children
studi
underli
medic
condit
prematur
birth
therefor
might
recommend
receiv
pz
conclus
identifi
rsv
pz
resist
mutat
children
receiv
pz
howev
child
confirm
breakthrough
infect
pz
resist
strain
although
rsv
pz
resist
mutat
uncommon
continu
effort
identifi
monitor
pz
resist
mutat
import
assess
role
breakthrough
infect
potenti
sustain
circul
popul
may
pose
threat
high
risk
group
receiv
pz
immunoprophylaxi
support
center
diseas
control
prevent
cooper
agreement
